EFA at Innovative Medicines Initiative (IMI) Open Info Day

On February 27th, David Brennan represented EFA at the IMI Open Info Day for its 5th Call for proposals in order to learn about the revised scientific research agenda. Due to the current involvement of EFA in the IMI project U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes), it is in our interest to follow how the IMI evolves in its future calls. The updated structure of the strategic research agenda includes additional priorities and adds six areas of IMI research interest, including patients. The IMI representatives continuously emphasised the necessity of maintaining a central role for patients within all of their projects going forward, which EFA of course very much welcomes. They cited U-BIOPRED as an exemplary case of partnership between science and patients, referring to it as an example of “best practice” for ensuring a link between research and the patients who may stand to benefit from its innovative results. For more information contact David Brennan at info@efanet.org

Leave a Reply

EFA eZine Archive